Present state of the
citicolina in
cerebral ischemia
NOTE: Translated
using software of
translation of
Spanish to English
Summary:
Introduccion: Citicoline has a neuroprotector effect since it reduces
the lesions of nerve membranes, by increase in the synthesis if
phospholipids, and reduces the levels of dree fatty acids.
In this study we review the existing data on the efficacy of
citicoline in the treatment of acute ischemic cerebrovascular disease
and its sequelae, both in animals and in clinical trials involving
patients. Development. In
various animal models citicoline reduces the volumen of cerebral
infarction and neurological sequelae and also potentiates the effects of
other neuroprotector drugs. On analysis of the literature, we found six
randomised clinical trials, double-blind and placebo-controlled en which
the effect of citicoline was evaluated in patients who had cute ischemic
cerebrovascular accidents. In
all of these it was found that citicoline reduced the neurological
sequelae. The finding of a
brod therapeutic window (24-48 hours) gives this an advantage over the
fibrinolytic agents, which have to be given within the first three to
six hours. In further
controlled trials carried out in patients with sequele of
cerebrovascular disease different degrees of neurological improvement
were found, although studies of greater duration are required to see
improvement in a longer term. Conclusions. With
the data available, we may affirm that citicoline us a safe, effective
drug, althougth clinical trials are still underway in larger populations
of patients. In these
trials not only the neurological state but also the area of infarction
are assesed to confirm their efficacy.
Autor:
Ecuadorian
magazine of neurology
